Emerge Australia Inc advocates for, educates about, and provides information on, Myalgic Encephalomyelitis (ME) more commonly known as Chronic Fatigue Syndrome (CFS). Established in 1980, Emerge Australia has been working with people affected by ME/CFS since then.
We believe that until a cure is found, people affected by ME/CFS can lead better lives by being understood and supported by the medical and general communities. Our role is to make sure that anyone affected by ME/CFS has the access they need to the support, education and advocacy that empowers them to make their lives more liveable.
ME/CFS affects men, women and children of all ages, cultures and socioeconomic backgrounds. Between 94,000 and 242,000 Australians are estimated to be affected by ME/CFS at any one time. There are varying degrees of severity, but around 25% of people are so profoundly affected by the condition they are bedbound and can be in constant pain. Full recovery is rare, with figures published in one report being a low 5 % . Symptoms are not limited to severe fatigue – they include a range of sleep, digestion, sensitivity, balance, brain dysfunction and pain issues.
The combination of these issues contributes to the deterioration of the quality of life for people with ME/CFS.
With members and supporters Australia-wide, Emerge Australia works to improve the quality of life for anyone affected by this debilitating condition.
To support, provide information and advocacy for people associated with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS).
Universal awareness and acknowledgement of ME/CFS as a medical condition.
To serve the best interests of people affected by ME/CFS with integrity, compassion and empathy.
Emerge Australia receives a small amount of very welcome funding from the Victorian state government and relies heavily upon membership contributions, donations and philanthropic support as well as the generous support of volunteers to remain operating.
 Cairns, R. and M. Hotopf. “A systematic review describing the prognosis of chronic fatigue syndrome.” Occup Med (Lond), 2005, 55(1): 20-31.